Start here if you're new
what it is
Niagen sells supplements and testing tied to NAD+, the cell-repair molecule your body makes less of as you age.
how it gets paid
Last year Niagen Bioscience made $129M in revenue. Tru Niagen direct-to-consumer was the main engine at $77.4M, or 60% of sales.
why it's growing
Revenue grew 29.9% last year. The business is finally showing operating leverage. Revenue grew 181% vs. prior year.
what just happened
Latest reported revenue reached $96M with EPS of $0.15 and gross margin of 64.3%.
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
25.4x trailing p/e — priced about right
18.5% return on capital — nothing to write home about
$0.11 fy2024 eps est
xvary composite: 40/100 — below average
What they do
Niagen sells supplements and testing tied to NAD+, the cell-repair molecule your body makes less of as you age.
NAD+ levels can fall by up to 65% between ages 30 and 70, according to the company business summary. Niagen sells you a product tied to that decline, through proprietary nicotinamide riboside ingredients and finished supplements. If your health routine starts with one branded capsule, switching gets personal fast.
How they make money
$129M
annual revenue · their business grew +29.9% last year
Tru Niagen direct-to-consumer
$77.4M
Distributor and retail sales
$38.7M
NAD+ test kits
$6.5M
Other healthy-aging products
$6.4M
The products that matter
nad+ supplement franchise
Tru Niagen® supplements
$129M · +30% growth
this is the only product on the page with real scale. at $129M and growing 30%, it still does most of the storytelling and most of the heavy lifting.
core driver
planned at-home injection kits
Niagen Plus at-home kits
H1 2026 target
planned for H1 2026, this is management's attempt to prove the company sells more than supplements. for a $383M company, one credible launch changes the math faster than it would at a large cap.
execution bet
skincare line extension
Niagen® Skincare Lab
$122B market
the pitch is simple: take the ingredient story into a $122B skincare market. the catch is simpler: this page gives you no revenue yet, so today this is optionality, not proof.
option value
Key numbers
29.9%
revenue growth
Sales growth jumped from a 14.0% historical pace to 29.9% on $129 million of revenue. Plain English: demand accelerated.
18.5%
return on capital
Return on capital → profit earned on money invested → so what: each dollar put into the business produced about $0.19 of operating return.
8.6%
operating margin
Operating margin → profit after running the business → so what: Niagen is profitable, but it is still far from a software-style cash machine.
$2M
long-term debt
Long-term debt is just $2 million, or 1% of capital. Plain English: the balance sheet is not what breaks this story.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $2M (1% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for NAGE right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Latest reported revenue reached $96M with EPS of $0.15 and gross margin of 64.3%.
The business is finally showing operating leverage. Revenue grew 181% vs. prior year, while EPS rose 200%, which means more of each new sales dollar is sticking.
$32M
revenue
$0.15
eps
64.3%
gross margin
the number that mattered
64.3% gross margin matters most because gross margin → money left after making the product → so what: it gives Niagen room to turn sales growth into real earnings.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the main risk here is simple: after selling one segment, management now has fewer places to hide if Tru Niagen slows or the H1 2026 product expansion disappoints.
med
the H1 2026 launch slips or lands softly
the company sold its analytical standards segment in feb 2026 and is pointing readers toward Niagen Plus at-home kits in H1 2026. that is a very specific timetable for a business this small.
if the launch slips past H1 2026, or if it arrives without visible demand, the market is left paying 25.4x earnings for a one-franchise story.
med
the revenue perimeter stays fuzzy
this page shows $100M total revenue and $129M for Tru Niagen alone. that mismatch might be definitional, but until investors can reconcile it, confidence in the model stays lower than it should.
when the inputs are fuzzy, the multiple usually deserves a discount. small caps do not get paid for making you guess.
med
valuation shrinks before the second act shows up
price stability is 5 / 100 and the 52-week range runs from $5 to $15. this stock does not need a catastrophe to reprice. it just needs investors to decide they want a cheaper entry.
a smaller valuation multiple hurts even if gross margin stays near 64.3% and the base business keeps selling product.
the combined risk picture is straightforward: most of the upside needs a successful H1 2026 launch, while most of the downside arrives if the market decides a volatile 25.4x story deserves less patience.
source: institutional data · regulatory filings · risk analysis
Pay attention to
timeline
H1 2026 kit launch
this is the calendar event that matters most. if it slips, the story gets smaller fast.
metric
the revenue reconciliation
the page shows $100M total revenue and $129M for Tru Niagen. you want management to make that easy to reconcile in filings and commentary.
risk
single-product concentration
if Tru Niagen cools before new formats contribute, there is not much else here to carry the story.
trend
volatility versus progress
with a 52-week range of $5–$15 and price stability at 5 / 100, you want business progress to start outrunning stock noise.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak, there is not a clean consensus worth leaning on.
risk profile
volatile
a 5 / 100 price stability score translates cleanly: this stock moves a lot even when the business barely changes.
chart momentum
catalyst-driven
this name trades harder on launch dates, product traction, and story resets than on smooth technical trends.
earnings predictability
45/100
that score means the business is still changing shape. translation: you should expect cleaner stories than cleaner quarters.
source: institutional data
Institutional activity
institutional ownership data for NAGE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive